StimGuard Names Executive Management Team to Complete Market Readiness for the World’s First Office Based OAB Stimulator System
POMPANO BEACH, Fla.--(BUSINESS WIRE)--Dec 2, 2019--
StimGuard, a privately-held, pre-commercial urology medical device company, today announced the formation of it’s executive management team, lead by Laura Tyler Perryman, who has been named CEO and President, to complete efforts to bring the first StimGuard product to market, the Chronic Afferent Nerve Stimulator (CANS), an office-based, fully percutaneously implantable device for the treatment of urgency urinary incontinence resulting from refractory overactive bladder (OAB) syndrome. StimGuard full product family includes neuromodulation therapies for incontinence, erectile and sexual dysfunction, and other urologic disorders.
The StimGuard team includes technology inventors and holders of over 41 patents for the wireless technology, Laura Perryman, CEO and President, Patrick Larson, Chief Technology Officer, Elizabeth Greene, Chief Compliance, Clinical and Regulatory Affairs Officer, Benjamin Speck, Chief Engineering Officer, Gil Bao, Interim Chief Financial Officer, and Ken Peters, MD, who is the company’s lead medical advisor. The team, along with a dozen other key personnel joining the StimGuard team developed and successfully commercialized the Stimwave Freedom Stimulator products from conception to serve over 10,000 patients. “We are thrilled to be positioned to leverage our innovative platform technology to benefit an entirely new underserved market with our wireless device urology solutions,” said Ms. Laura Tyler Perryman, CEO and President of StimGuard. Stimwave efforts will continue to be supported by the founding team, with commercialization efforts lead by Mr. Paul LaViolette as Interim CEO, former COO of Boston Scientific.
The StimGuard device utilizes wireless technology to activate the afferent micturition (neural urinary) pathways and is placed through a needle at the tibial nerve in a minimally-invasive, office-based procedure. The StimGuard device is pre-market, and investigational through the Food and Drug Administration Investigational Device Exemption for future premarket application. This device is in stark contrast to sacral nerve stimulation that has been the gold-standard for incontinence neuromodulation for more than 20 years, is done in an operating room under anesthesia with fluoroscopic imaging and involves implantation of electrodes at the sacral nerve and a battery unit that lasts only four to five years, or alternatively would need to be recharged often for newer models.
More than 37 million Americans – one out of every six adults – live with some level of OAB. OAB treatment varies depending on the severity of the symptoms, with the estimated cost to the U.S. healthcare system at more than $60 billion per year.
StimGuard is a privately held medical device company engaged in the development, manufacture, and pre-commercialization of wirelessly powered, microtechnology neurostimulators, providing patients with a convenient, safe, minimally invasive, and highly cost-effective urological solution that is easily incorporated into their daily lives. StimGuard’s goal is to evolve its patented, cutting-edge platform into the default for neuromodulation, increasing the accessibility for patients worldwide while lowering the economic impact of urology care management. www.stimguard.com
View source version on businesswire.com:https://www.businesswire.com/news/home/20191202005452/en/
Evan Nicholson, Rosemary O’Brien, Kati Stadum or Sarah Rogers at Glodow Nead Communications, 415.394.6500 email@example.com
KEYWORD: UNITED STATES NORTH AMERICA FLORIDA
INDUSTRY KEYWORD: MEDICAL DEVICES HEALTH
Copyright Business Wire 2019.
PUB: 12/02/2019 06:55 AM/DISC: 12/02/2019 06:55 AM